Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association Clinical & Scientific Conference

robot
Abstract generation in progress

Avidity Biosciences (Nasdaq: RNA) announced it will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The presentations will cover new data from their EXPLORE44 program for Duchenne muscular dystrophy (DMD44) and insights into myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD). Additionally, Avidity will host an industry forum lunch focusing on biomarker advancements in rare neuromuscular diseases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)